mediKOL Insight: Where next for MS? : Market Research Report

mediKOL Insight: Where next for MS?

Published by: mediKOL Ltd.

Published: Dec. 1, 2008 - 122 Pages

Contents
Table of Contents
Introduction
Report Overview
KOL’s
Executive Summary: Executive Summary; Conclusions
Commercial Outlook: Comparative Product Attributes; Market Development Scenarios 1, 2, 3; Future Market Scenarios 1, 2 & 3; The mediKOL View
Disease Synopsis: MS Overview; Epidemiology; Diagnosis; Treatment; Current Market; The mediKOL View
Current Landscape: The Market; Overview; Product Summary; Historic Market Development; US Pricing; Drug Treatments
Future Landscape: R&D Overview; Key R&D Issues; Key R&D Candidates; The KOL View; The mediKOL view
Conclusions
List of Tables & Charts included in this report:: Global Multiple Sclerosis Market ($m) 2004-2007; Split by Leading Products; Leading Products & New Therapies - Perceived Efficacy vs Safety/Side-Effect Issues; Key Events by Product Timeline: 2008-2013; Scenario 1: “Safer Brands Take Over”; Scenario 2: “Tysabri and Fingolimod First Line”; Scenario 3: “Status Quo Continues”; Key Products incl. R&D Compounds: Perceived Efficacy vs Year of Launch (by Route of Administration); New Therapies (by Route of Administration): Perceived Efficacy vs Safety/Side-Effect Issues - I; New Therapies (by Route of Administration): Perceived Efficacy vs Safety/Side-Effect Issues - II, Tysabri and fingolimid demonstrate low risk of PML; Scenario 1: “Safer Brands Take Over”, Scenario 2: “Tysabri and Fingolimod First Line” & Scenario 3: “Status Quo Continues”; Global Multiple Sclerosis Market ($m) 2004-2014; Scenarios 1-3; Global Multiple Sclerosis Market ($m) 2004-2014; Scenario 1 (sales split by Product / Product Group; Global Multiple Sclerosis Market ($m) 2004-2014; Scenario 2 (sales split by Product / Product Group; Global Multiple Sclerosis Market ($m) 2004-2014; Scenario 3 (sales split by Product / Product Group; Global Immunomodulator Market ($m) 2004-2014; Global Oral Immunomodulator Market ($m) 2004-2014

Abstract

The MS landscape is poised to change dramatically over the next 4 - 7 years as a number of hotly anticipated new therapies enter the latter stages of development with fascinating implications for all stakeholders.

This report provides an in-depth and insightful appraisal of the current and future MS market. It is driven principally by the views of a panel of internationally recognised key opinion leaders (KOLs), whose opinions on the current and future clinical environment are distilled, analysed and presented in clear and insightful commercial terms. More specifically, the report is focused on three potential future scenarios that illustrate how the MS market might evolve based on commercial, clinical and regulatory events, and underpinned by our KOL discussions. The report also presents an overview and appraisal of the key clinical trials together with an analysis of their potential impact on the future market. Individual product and market forecasts are compared and contrasted with ‘consensus’ forecasts supplied under licence from EvaluatePharma®.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

mediKOL Insight: Where next for MS?

Table of Contents

Abstract